| Entries |
| Document | Title | Date |
|---|
| 20080249286 | HIGH-PRESSURE REFOLDING OF PROTEINS IN THE PRESENCE OF BINDING PARTNERS - Methods for producing biologically active protein from aggregated and/or denatured proteins which comprise subjecting the protein to high hydrostatic pressure in the presence of a ligand or specific binding agent are disclosed. The ligand can be a macromolecule, such as another protein, a nucleic acid, or other macromolecules, or the ligand can be a small organic molecule. | 10-09-2008 |
| 20080281085 | Methods And Kits For Folding Proteins - The invention relates to methods for folding protein comprising providing an aqueous solution of a protein in non-native conformation and a linear or branched sugar polymer comprising three or more saccharide units, or a derivative thereof at a concentration suitable to permit folding of the protein and incubating the solution to permit folding of the protein. | 11-13-2008 |
| 20080287660 | Novel OrfF and OrfF' polypeptides, nucleic acid molecules encoding the polypeptides and applications thereof - The invention relates to novel pathogenic OrfF and OrfF′ polypeptides derived from | 11-20-2008 |
| 20080300385 | Covalently-linked complexes of HIV Tat and Env proteins - Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is important to the binding properties of the complexes, and so is controlled to avoid the loss of Env's ability to bind specifically to CD4 and Tat's ability to bind specifically to anti-Tat monoclonal antibodies. | 12-04-2008 |
| 20080312424 | METHOD AND COMPOSITIONS FOR THE DETECTION OF PROTEIN GLYCOSYLATION - The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes. | 12-18-2008 |
| 20090005541 | GAG BINDING PROTEIN - A method is provided for introducing a GAG binding site into a protein comprising the steps:
| 01-01-2009 |
| 20090005542 | Hydrolysable polymeric FMOC- linker - The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs. | 01-01-2009 |
| 20090012274 | Unsaturated aldehyde surfaces and methods of molecular immobilization - The disclosure provides an article including a substrate having a surface modified with an unsaturated aldehyde, for example, of the formula: | 01-08-2009 |
| 20090012275 | Means and methods for mediating protein interference - The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications. | 01-08-2009 |
| 20090023901 | Degradable Clostridial Toxins - The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain. | 01-22-2009 |
| 20090036654 | Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof - The present invention relates to human Rho-kinase I (ROCK I), ROCK I binding pockets, ROCK I-like binding pockets. More particularly, the present invention provides a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to ROCK I protein or ROCK I protein homologues, or complexes thereof. The invention also relates to crystallizable compositions and crystals comprising ROCK I kinase domain and ROCK I kinase domain complexed with an inhibitor of that domain. The invention also relates to methods of identifying inhibitors of the ROCK I kinase domain. | 02-05-2009 |
| 20090043079 | CELL CULTURE SURFACES HAVING HYDROGEL SUPPORTED PROTEINS - A method is disclosed herein for treating a polymeric surface to define an improved cell culture surface. The method includes the steps of: coating the polymeric surface with a hydrogel; and attaching proteins to the hydrogel-coated surface. Advantageously, a method is provided which consistently produces improved cell culture surfaces that generally avoid bare spots and possible undesired protein absorption or cell differentiation. | 02-12-2009 |
| 20090054632 | Hydrophobically-modified protein compositions and methods - Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle. | 02-26-2009 |
| 20090054633 | Method for Controlling Stability of Nanofabricated Polypeptide Multilayer Films, Coatings, and Microcapsules - Disclosed herein is a method of controlling the stability of multilayer polypeptide films. A method of controlling the stability of a film, comprises exposing the film to an oxidizing agent or a reducing agent, wherein the film comprises a plurality of layers, the layers comprising alternating oppositely charged polypeptides, wherein a first layer comprises a first layer polypeptide and a second layer comprises a second layer polypeptide, and the first layer polypeptide comprises a sulfhydryl-containing amino acid. | 02-26-2009 |
| 20090069547 | STABILIZATION OF MAMMALIAN MEMBRANE PROTEINS BY SHORT SURFACTANT PEPTIDES - The present invention provides for a method and kits for stabilizing mammalian membrane protein using short surfactant peptides. The mammalian membrane protein can be a G protein-coupled receptor. | 03-12-2009 |
| 20090069548 | Immobilized Proteins and Methods and Uses Thereof - The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods and kits that utilize such immobilized proteins, such as a microdevice or “protein chip”, a high-throughput screening device, and for the microscopy of proteins on a surface. | 03-12-2009 |
| 20090082551 | Method, compositions and classification for tumor diagnostics and treatment - The present invention is directed towards classifying tumor biomarkers, particularly membrane receptors, and more particularly the gastrin-releasing peptide (GPR) receptors, identified in patient samples, then linking therapeutic agents (chemical, radiological, or biological) to patient-specific ligands that bind to such receptors, clinicians can produce diagnostic and treatment compositions and implement treatment regimens which, by using the classified and identified biomarkers, and due to their improved accuracy, increase success and decrease undesired side effects from such treatments. | 03-26-2009 |
| 20090088559 | Method for preparing modified polypeptides - Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve
| 04-02-2009 |
| 20090093619 | Human T2R51 Nucleic Acid Sequences and Polypeptides - Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. | 04-09-2009 |
| 20090105464 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND DNA - A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus useful as a medicine for curing circulation diseases, e.g. cardiac edema, nephric edema, hepatic edema, pulmonary edema, hypertension, congestive heart failure, and acute and chronic renal failure. | 04-23-2009 |
| 20090118474 | Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 05-07-2009 |
| 20090131641 | Method for assembling subunits into capsoids - The invention relates to a method for assembling subunits forming capsoides in a solution containing a reduction agent in order to obtain capsoides. Initially, the reduction agent is inactivated or removed from the solution, subsequently, the ionic strength in the solution is increased to such an extent by adding at least one salt to the solution, that the subunits are assembled into capsoides. | 05-21-2009 |
| 20090137785 | RAB9 PROTEIN CRYSTAL STRUCTURES AND METHODS FOR IDENTIFYING RAB9 MODULATORS - The present invention relates to crystalline Rab9 in complex with either GDP or the GTP analog Guanosine 5′-(β,γ-imido) triphosphate (GppNHp), the three dimensional coordinates and structures of Rab9 in Rab9-GDP and Rab9-GppNHp complexes, and uses thereof for drug design. In particular, the present invention relates to methods for producing Rab9 crystals of sufficient quality to obtain a determination of the three dimensional structure of Rab9 to a high resolution in both its GTP-bound (on/active) and GDP-bound (off/inactive) conformations. The present invention also relates to a computer-readable medium encoded with the three dimensional coordinates of Rab9 in Rab9-GDP and Rab9-GppNHp complexes wherein, using a graphical display software program, the three dimensional coordinates create an electronic file that can be visualized on a computer capable of representing the electronic file as a three dimensional image. | 05-28-2009 |
| 20090156791 | MOLECULE TRANSFER/DELIVERY SYSTEM - A molecule transfer and delivery system includes a loading zone ( | 06-18-2009 |
| 20090176971 | Method for Determining Thermal Stability of Collagen or Collagen-Like Peptide - The present invention is a method for determining the thermal stability of a collagen peptide, collagen-like peptide or triple-helix construct with the repeating peptide unit Gly-Xaa | 07-09-2009 |
| 20090182128 | Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 07-16-2009 |
| 20090187009 | SCALE-UP METHODS AND SYSTEMS FOR PERFORMING THE SAME - The present invention provides methods of and systems for translating conditions from a small-volume experiment to a larger-volume experiment. | 07-23-2009 |
| 20090187010 | Method of arranging ferritin and method of arranging inorganic particles - To provide a method of arranging ferritin by which a high rate of the number of the molecular film spots on which sole ferritin molecule was arranged in effect, with respect to total number of the molecular film spots provided for arranging ferritin (sole arrangement rate) is achieved is objected to. Specifically, in Fer8 ferritin having a sequence excluding 7 amino acids of from the second to the eighth, from an amino acid sequence (Fer0 sequence) translated from a naturally occurring DNA sequence, lysine at position | 07-23-2009 |
| 20090192296 | Method for Producing Denatured Substance of Lactalbumin - It is intended to provide a method for producing a denatured substance of lactalbumin, particularly the substance showing a cell death inducing activity against a tumor cell, simply at a low cost. The method for producing a denatured substance of lactalbumin includes heating a mixture of domestic animal milk and oleic acid. The method of the invention can produce a useful substance as a pharmaceutical which induces cell death of a tumor cell such as solid cancer or a leukemic lymphocyte from domestic animal milk which is an extremely inexpensive raw material and has advantages that the raw material can be obtained easily, supply of the raw material is stable, the raw material is inexpensive and the like. Further, the method is industrially advantageous because it has characteristics that a large amount of the tumor cell death inducing substance can be produced by a batch reaction, a column treatment is not required and the like. | 07-30-2009 |
| 20090192297 | CARBON MEMBRANE HAVING BIOLOGICAL MOLECULE IMMOBILIZED THEREON - Disclosed is a biological molecule-immobilized carbon membrane which comprises a porous carbon membrane and a biological molecule (e.g., an enzyme) immobilized on the carbon membrane, wherein the porous carbon membrane has three-dimensional cancellous pores through which fluid can permeate. The carbon membrane can have a large amount of a biological molecule (e.g., an enzyme) immobilized thereon and can also have a higher level of enzymatic activity or the like compared to a conventional one. Therefore, the carbon membrane is useful as an electrode for a bio-sensor or a bio-fuel cell. | 07-30-2009 |
| 20090192298 | Through-bond energy transfer cassettes, systems and methods - The present disclosure relates, according to some embodiments, to compositions, systems, and methods for preparing and using fluorescent through-bond energy transfer cassettes. | 07-30-2009 |
| 20090192299 | NANOLIPOPROTEIN PARTICLES AND RELATED METHODS AND SYSTEMS FOR PROTEIN CAPTURE, SOLUBILIZATION, AND/OR PURIFICATION - Provided herein are methods and systems for assembling, solubilizing and/or purifying a membrane associated protein in a nanolipoprotein particle, which comprise a temperature transition cycle performed in presence of a detergent, wherein during the temperature transition cycle the nanolipoprotein components are brought to a temperature above and below the gel to liquid crystalling transition temperature of the membrane forming lipid of the nanolipoprotein particle. | 07-30-2009 |
| 20090203888 | Isolated Photoprotein Aqdecay, and Its Use - The invention relates to the photoprotein AQdecay, to its nucleotide and amino acid sequences and to the activity and use of the photoprotein AQdecay. | 08-13-2009 |
| 20090318673 | METHOD OF CHANGING FLUORESCENCE WAVELENGTH OF FLUORESCENT PROTEIN - The present invention provides: a method of changing the fluorescence wavelength of a GFP-like fluorescent protein from copepod while maintaining recombinant expression efficiency, which comprises identifying a structural factor for determining the fluorescence wavelength thereof in the three-dimensional structure of the protein and modifying amino acid residues associated with the structural factor; and a modified fluorescent protein obtained by applying said method. For example, with regard to a GFP-like fluorescent protein from | 12-24-2009 |
| 20100016562 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS - Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy. | 01-21-2010 |
| 20100022758 | PYROGLUE - The present invention relates to an adhesive material being composed and/or consisting of at least one protein obtained or obtainable from fimbriae from archaea. Furthermore, the present invention relates to the use of at least one protein obtained from fimbriae from archaea for the preparation of an adhesive material and a method for the preparation of an adhesive material comprising the step of isolating and/or purifying at least one protein obtained from fimbriae from archaea. | 01-28-2010 |
| 20100022759 | POLYMER AND FLUORESCENCE PROBE HAVING THE POLYMER - A polymer has a fluorescent dye sensitive to a hydrophobic environment. When a pH around the polymer decreases within a range of pH of equal to or greater than 5.5 and less than 7.4, and a secondary structure of the polymer changes from a random coil to a helix. | 01-28-2010 |
| 20100029911 | Method For Solid-Phase Peptide Synthesis And Purification - Use of an activated solid phase and a peptide-conjugated anchoring part for solid phase peptide synthesis, wherein the anchoring part is coordinatively and reversibly attached to the activated solid phase. | 02-04-2010 |
| 20100029912 | Fusion Protein - Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells. | 02-04-2010 |
| 20100041875 | MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COPLEXES, AND USES THEREOF - This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes. | 02-18-2010 |
| 20100048879 | MULTIMERISED HIV FUSION INHIBITORS - There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS. | 02-25-2010 |
| 20100056765 | Formulations That Inhibit Protein Aggregation - Disclosed is a stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein. Also disclosed are methods for preparing such formulations and methods for inhibiting protein aggregate formation induced by physical stresses associated with processing, manufacture, shipping, and storing protein formulations, particularly freeze/thaw stress. | 03-04-2010 |
| 20100063261 | Affinity chromatography matrices and methods of making and using the same - The invention provides methods of coupling protein ligands to a solid support. The invention also provides affinity chromatography matrices and methods of using affinity chromatography matrices to purify a target molecule. | 03-11-2010 |
| 20100076180 | Method of fixing rail molecule and nano transport device - An object is to move a rail molecule by means of a biomolecular motor deposited on a base and inactivate the biomolecular motor through irradiation with light having a predetermined wavelength, to thereby readily and reliably fix the rail molecule at a predetermined position, while orienting the rail molecule in a predetermined direction without employment of any reagent. A method for fixing a rail molecule which has polarity and on which a biomolecular motor moves in a direction corresponding to the polarity includes depositing a biomolecular motor on a base; moving a rail molecule by means of the biomolecular motor; and inactivating the biomolecular motor by irradiating the biomolecular motor with light having a predetermined wavelength when the rail molecule reaches a predetermined position, to thereby fix the rail molecule so that it is oriented in a predetermined direction. | 03-25-2010 |
| 20100105879 | SUPPORT HAVING PROTEIN IMMOBILIZED THEREON AND METHOD OF PRODUCING THE SAME - A method of producing a protein-immobilized support includes immobilizing a protein having a tag sequence on a support, the tag sequence including a sequence that includes three or more consecutive basic amino acids. | 04-29-2010 |
| 20100105880 | PURIFICATION OF CARBON NANOTUBES VIA BIOMOLECULES - Separating different types of nanotubes from one another includes providing a sample of heterogeneous nanotubes comprising a first and second type of carbon nanotube; providing a first type of molecule; introducing the first type of molecule to the sample; binding the first type of molecule to the first type of carbon nanotube; and separating the first type of carbon nanotube from the sample. A second type of molecule may be introduced to the sample followed by binding the second type of molecule to the second type of carbon nanotube; and separating the second type of carbon nanotube from the sample. The sample may comprise a third type of carbon nanotube. A third type of molecule may be introduced to the sample followed by binding the third type of molecule to the third type of carbon nanotube; and separating the third type of carbon nanotube from the sample. | 04-29-2010 |
| 20100105881 | METHOD FOR PURIFYING MARINE COLLAGEN AND THE PROCESSING THEREOF INTO POROUS SPONGES - Methods are provided for purifying marine collagen and for processing the collagen into porous sponges. Products produced with these methods and the use of the products are also provided. | 04-29-2010 |
| 20100121039 | METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS - Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent. The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule. | 05-13-2010 |
| 20100137566 | Compounds and Methods Used to Treat Infectious Diseases - The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught. | 06-03-2010 |
| 20100160612 | MUTEINS OF TEAR LIPOCALIN WITH AFFINITY FOR THE T-CELL CORECEPTOR CD4 - The present invention relates to a mutein of human tear lipocalin, wherein the mutein comprises at least one mutated amino acid residue at any two or more of the sequence positions 24-36, 53- 66, 79-84, and 102-110 (or 103-110) of the linear polypeptide sequence of the mature human tear lipocalin, and wherein the mutein binds to the extracellular region of the T-cell coreceptor CD4 with detectable affinity. The invention also relates to a method of generating such a mutein as well as to various pharmaceutical uses of such a mutein. | 06-24-2010 |
| 20100160613 | METHOD FOR HIGH SPATIAL RESOLUTION STOCHASTIC EXAMINATION OF A SAMPLE STRUCTURE LABELED WITH A SUBSTANCE - A method for high spatial resolution stochastic examination of a biological sample structure labeled with a labeling substance is described. The method comprises providing a biological sample structure; choosing such a labeling substance that has molecules present in a first state and in a second state, and the first and second states differ from one another in at least one photophysical property such that there is sufficient probability that one portion of the molecules of the substance will be in the first state and another portion of the molecules will be in the second state and within which labeling substance a change of the state of the molecules can occur spontaneously between the two states in both directions; and labeling the biological sample structure with the substance. | 06-24-2010 |
| 20100168402 | Direct Attachment of Polypeptides to Virus Like Particles - Compositions and methods are provided for the control of direct protein attachment to virus like particles where virus structural proteins that have been modified to comprise an unnatural amino acid at a pre-determined site are reacted with one or more “display” polypeptides that also comprise an unnatural amino acid at a pre-determined site in a one step reaction. The compositions of the invention are useful for various purposes where it is desirable to efficiently and directly attach multiple polypeptides to a single carrier entity, particularly where two or more different polypeptides are attached to a single carrier. | 07-01-2010 |
| 20100204457 | PREPARATION OF ANNEXIN DERIVATIVES - Labeled annexin is formed by reacting annexin or a modified annexin with a phosphatidylserine group or an analogue of phosphatidylserine. This phosphatidylserine annexin conjugate is then reacted with an appropriate label to form a labeled annexin and the annexin is separated from the phosphatidylserine group. The reaction between the phosphatidylserine group and the annexin is calcium ion concentration dependent. Therefore, the reaction can be promoted by having a high calcium ion concentration and the separation of the phosphatidyl group from the annexin group is facilitated by reducing the calcium ion concentration preferably by addition of an appropriate calcium chelating agent. | 08-12-2010 |
| 20100210827 | Preparation Method Of Recombinant Protein By Use Of A Fusion Expression Partner - The present invention relates to a preparation method using a fusion expression partner. The method includes preparing a polynucleotide encoding a fusion expression partner selected from the group consisting of SlyD (FKBR type peptidyl prolyl cis-trans isomerase). Crr (glucose-specific phosphotransferase (PTS) enzyme IIA component). RpoS (RNA polymerase sigma factor) PotD (Spermidine/putrescine-binding periplasmic protein), and RpoA (RNA polymerase alpha subunit), and an expression vector linking a polyDNA fragment of a heterologous protein, preparing a transformant by introducing the expression vector into a host cell, inducing the expression of a recombinant protein by culturing a transformant, and obtaining the expression. In the preparation method of the recombinant protein, the heterologous protein may enhance the water-solubility and folding of the recombinant protein, overcome the limitations about the water-solubility and folding which the conventional fusion expression partners have, and be used widely in the production of pharmaceutical and industrial proteins. | 08-19-2010 |
| 20100228009 | Labeled Biomolecular Compositions and Methods for the Production and Uses Thereof - Disclosed herein is a set of | 09-09-2010 |
| 20100305309 | NANODIAMOND PARTICLE COMPLEXES - The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc. | 12-02-2010 |
| 20110003975 | METHOD OF DENATURING WHEY PROTEIN - Provided is a method of producing a denatured whey protein which has an improved heat stability without using an additive such as an organic solvent. Also provided is a denatured whey protein produced by this method. A method of producing a denatured whey protein which comprises contacting and mixing a whey protein solution with a whey protein solution that is flowing as a thin film in the form of a rotating cylinder, and thus shearing the same at a temperature ranging form 76 to 120° C. at a shear speed of 5,000 s | 01-06-2011 |
| 20110009603 | Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 01-13-2011 |
| 20110015375 | Methods for Identifying and Using MarR Family Polypeptide Binding Compounds - Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides. | 01-20-2011 |
| 20110028700 | MUTANT PROTEINS AND METHODS FOR PRODUCING THEM - A method of producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to its parent GPCR, the method comprising: a) providing one or more mutants of a first parent GPCR with increased stability relative to the first parent GPCR b) identifying in a structural membrane protein model the structural motif or motifs in which the one or more mutants have at least one different amino acid residue compared to the first parent GPCR, and c) making one or more mutations in the amino acid sequence that defines a corresponding structural motif or motifs in a second parent GPCR, to provide one or more mutants of a second parent GPCR with increased stability relative to the second parent GPCR. Mutants of β-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed. | 02-03-2011 |
| 20110071280 | Methods and Compositions for Concentrating Secreted Recombinant Proteins - Methods and compositions are described that relate to obtaining concentrated preparations of secreted recombinant proteins. These proteins are expressed in the form of fusion proteins with a chitin-binding domain (CBD). The fusion proteins are capable of being concentrated in the presence of chitin. Also described is: a shuttle vector that includes a modified LAC4 promoter; a chitinase-negative host cell; a CBD capable of eluting from chitin under non-denaturing conditions; and sterilized chitin, which can be optionally magnetized for facilitating recovery of recombinant protein. | 03-24-2011 |
| 20110071281 | Electrolysis for protein modification - The present invention relates to a method of protein electrolysis, comprising: (a) providing a protein sample, which contains a salt selected from alkali metal salts or alkaline earth metal salts having a concentration of 20 mM or above; (b) electrolytically reducing said protein sample; (c) obtaining an electroreduced protein sample. The present invention also relates to a protein obtained by the above-mentioned protein electrolysis method, and a use of said method for protein modification. | 03-24-2011 |
| 20110269945 | FLUORESCENT PROTEIN - An object of the present invention is to provide a novel fluorescent protein derived from | 11-03-2011 |
| 20110301341 | MODIFIED ORGANS AND CELLS FOR XENOTRANSPLANTATION - It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an α-galactosyl (Gal) epitope, for example, Galα(1->3)Galβ(1->4)GlcNac (linear B type 2) or Galα(1->3)Galβ(1->4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced. or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans. Cells can be rendered even more compatible by genetically engineering the animal to express a human complement regulatory protein (inhibitor), such as CD59, on its cells, or to express an excess of a pig complement regulatory protein. | 12-08-2011 |
| 20110319602 | T2R TASTE RECEPTORS AND GENES ENCODING SAME - Functional assays that detect the effect of a particular compound or compounds on the activation of at least one human T2R polypeptide are provided. These assays include e.g., assays which detect the effect of said compound on intracellular calcium, second messengers such as cAMP, cGMP, current e.g., by use of voltage-clamp or patch-clamp, techniques, fluorescence polarization or FRET assays, and the like. These assays are useful in identifying compounds that putatively elicit or modulate (inhibit or enhance) bitter taste in human subjects, e.g. bitter taste blockers. The effect of identified compounds on taste may be further evaluated in human or animal taste tests. | 12-29-2011 |
| 20120016111 | Compositions for the treatment of cancer, and methods for testing and using the same - A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of | 01-19-2012 |
| 20120046453 | PROTEIN CHARGE REGULATOR AND PROTEIN-ENCAPSULATING POLYMER MICELLE COMPLEX - The present invention provides a protein delivery means (e.g., a polyion complex) which allows efficient introduction into cells (particularly into the cytoplasm), is highly stable in serum, and is also widely applicable. The polyion complex of the present invention comprises a cationic polymer having a polycation moiety and a charge-conversional protein whose overall charge is converted from basic or neutral to acidic by a specific charge regulator. | 02-23-2012 |
| 20120083591 | METHOD OF PRODUCING A SET OF MHC MOLECULES - The present invention relates to a method of producing a set of MHC molecules, and more precisely to a method of producing a set of MHC molecules which differ in their peptide bound in the binding groove. The method allows for parallel and rapid synthesis of different MHC molecules at high yields for each molecule. | 04-05-2012 |
| 20120226027 | Methods and Compositions for Selective Labeling of Different Biotinylated Targets within Multicolor or Multilabel Assays - Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches. | 09-06-2012 |
| 20120245331 | MODIFIED BIOTIN-BINDING PROTEIN - The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of:
| 09-27-2012 |
| 20120245332 | MHC OLIGOMERS, COMPONENTS THEREOF, AND METHODS OF MAKING THE SAME - The present invention relates to an MHC binding polymer suitable for the oligomerisation of individual MHC monomers. The MHC binding polymer comprises a first segment and a second segment, wherein the first segment comprises a peptide capable of binding in a binding groove of an MHC molecule, and wherein the second segment comprises a linking segment and a recognition site for coupling the MHC binding polymer with a specific partner. The linking segment is a polymer with a length of at least 10 Angstrom in its native conformation. Further it relates to an MHC oligomer containing such MHC binding polymers. Individual functional MHC complex monomers are oligomerised via their peptides bound in the peptide binding groove of the complex. Moreover, it relates to a method of making such MHC binding polymer and oligomer and various methods using the same. | 09-27-2012 |
| 20130102763 | Method of thermostabilization of a protein and/or stabilization towards organic solvents - Thermostabilization of a protein where the protein contains access routes and wherein at least one amino acid in the bottleneck of the access route is mutated, includes identifying the amino acids of the bottleneck and the amino acids control exchange of the solvent between a buried protein core and surrounding environment and/or in the packing of the amino acids inside the access route. Modification of the amino acids are determined so that the packing of the amino acids inside the tunnel is improved and the access route prevents access of undesired solvent molecules to the protein core, while allowing passage of the compounds necessary at the protein core to enable the protein to perform its biological function. | 04-25-2013 |
| 20130137858 | IMMOBILIZED PROTEINS AND METHODS AND USES THEREOF - The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods and kits that utilize such immobilized proteins, such as a microdevice or “protein chip”, a high-throughput screening device, and for the microscopy of proteins on a surface. | 05-30-2013 |
| 20130289254 | CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE - An object of the present invention is to provide a cell-adhesive material for biological tissues, in which the surface of a material for biological tissues (particularly metallic material) is modified strongly with a large amount of a cell-adhesive artificial peptide (P) that retains a biological activity. | 10-31-2013 |
| 20140081007 | Methods For The Detection, Analysis And Isolation of Nascent Proteins - This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes. | 03-20-2014 |
| 20140187757 | METHODS AND COMPOSITIONS - The invention relates to a complex comprising a phage particle, said phage particle comprising
| 07-03-2014 |
| 20140288282 | Processes For Producing Protein Microparticles - Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients. | 09-25-2014 |
| 20140316116 | METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS - A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed. | 10-23-2014 |
| 20140323701 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 10-30-2014 |
| 20150376228 | PROCESS FOR HIGH EFFICIENCY REFOLDING OF RECOMBINANT PROTEINS - A process of refolding a recombinant protein from inclusion bodies (IBs) formed inside a host cell, is provided. The process includes homogenising a wet cells slurry to obtain a cell lysate; incubating the cell lysate with a reducing agent to obtain a reduced cell lysate; isolating reduced IBs from the reduced cell lysate to obtain isolated IBs; solubilising the isolated IBs with a denaturing agent to obtain solubilised IBs; and subjecting the solubilised IBs to a unit process of refolding to obtain a refolded recombinant protein. | 12-31-2015 |
| 20160159853 | APPARATUS FOR REFOLDING OF RECOMBINANT PROTEINS - A machine or apparatus for refolding a protein of interest produced recombinantly in a host cell in form of inclusion bodies is provided. The apparatus includes an inclusion bodies (IB) solubilisation tank to solubilise the inclusion bodies; a plurality of refolding vessels or reactors arranged in series to receive a refolding feed; a first tank connected to the IB solubilisation tank to hold diafiltration buffer or agent; a first diafiltration cartridge having at least one permeate end and one retentate end, connected to the IB solubilisation tank, through a first retentate end to feed the refolding feed to the IB solubilisation tank; a second tank, connected to the first permeate end of the diafiltration cartridge to receive and recycle the refolding buffer and each of the refolding vessels, for supplying refolding buffer or agent to each of the refolding vessels. | 06-09-2016 |
| 20160166707 | Stabilization of Therapeutic Agents to Facilitate Administration | 06-16-2016 |
